|
 |
|||||||
 |
ORGANOSELENONESOrganoselenones are selenium-containing drugs that belong to the alkylating class of chemotherapy. Alkylating agents are the most broadly used anticancer agents in the world. However, the effectiveness of current alkylating agents is limited since a majority of cancers develop drug resistance. Common drug-resistance mechanisms to alkylating agents include thiol resistance, alkyl transferase elevation and multidrug resistance. Accordingly, the Company believes there is potential for new products to address drug resistance in cancer therapy. ADVENTRX is developing various compounds in its organoselenones program based on their broad anticancer activity and potentially lower susceptibility to drug resistance mechanisms. Preclinical studies have shown effectiveness of organoselenones against multiple tumor types, including breast, lung, ovarian, head/neck cancer, leukemias and lymphomas. Organoselenones have also shown anti-tumor activity against tumor cell lines with prior drug resistant profiles, including tumor cell lines resistant to other alkylating agents. Under a license from the University of Southern California, the Company has exclusive rights to a patent claiming a method of treating drug resistant cancers by administering one or more organoselenone compounds. Further preclinical testing of the organoselenones is planned in order to determine a potential lead compound from this family of drugs that may be moved into human testing in the future. |
